Most Read Articles
3 months ago
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Catherine J Calderwood, MA (Cantab), MRCOG; Omar I Thanoon, MRCOG, 3 years ago

One of the many early physiological adaptations of pregnancy involves changes in the coagulation system, which promote coagulation and impair fibrinolysis. The physiological goal is to prepare for the haemostatic challenge of delivery. A ‘side effect’ of this change is an increased risk of thrombosis. All pregnant women are therefore at risk of thrombosis, compared with non-pregnant women. This risk is manifest from early in the first trimester until 4−6 weeks post partum.

one year ago
Routine laboratory factors predict adverse pregnancy outcomes of patients with intrahepatic cholestasis of pregnancy, according to a prospective, case control study.

Dutasteride does not increase CV risk relative to finasteride

13 days ago

It appears that dutasteride does not elevate the risk of cardiovascular (CV) events in relation to finasteride, suggest the results of a recent population-based cohort study.

To investigate the risk of CV events among patients receiving dutasteride (n=36,311) compared with finasteride (n=36,311), researchers analysed Ontario men (≥66 years) who commenced treatment with dutasteride or finasteride between 1 October 2005 and 31 March 2015. Participants were matched 1:1 based on a propensity score and calendar quarter of treatment initiation to account for temporal changes in prescribing.

Hospitalization for heart failure was the primary outcome. Secondary analyses were performed to examine acute myocardial infarction and stroke. To adjust for differences between groups, researchers used Cox proportional hazards regression.

Primary analysis showed no difference in the risk of heart failure among patients receiving dutasteride relative to those receiving finasteride (adjusted hazard ratio [HR], 0.98; 95 percent CI, 0.88 to 1.08). Similarly, there was no difference observed in the risk of acute myocardial infarction (HR, 0.94; 0.82 to 1.08) or stroke (HR, 1.03; 0.88 to 1.20).

A study by Cindolo and colleagues in 2013 suggested that the clinical effects of dutasteride and finasteride might be different. Patients treated with dutasteride appeared to be less likely to have benign prostatic hyperplasia-related hospitalization. [World J Urol 2013;31:665-71; Arch Ital Urol Androl 2013;85:200-6]

In another study, a retrospective analysis of data from consecutive patients treated at a single clinic found that both finasteride and dutasteride were effective for the management of lower urinary tract symptoms. However, dutasteride had significantly more sexual side effects and breast complications than finasteride. [Int J Clin Pract 2012;66:1052-5]

Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, while finasteride selectively inhibits the type 2 isoform, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
3 months ago
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Catherine J Calderwood, MA (Cantab), MRCOG; Omar I Thanoon, MRCOG, 3 years ago

One of the many early physiological adaptations of pregnancy involves changes in the coagulation system, which promote coagulation and impair fibrinolysis. The physiological goal is to prepare for the haemostatic challenge of delivery. A ‘side effect’ of this change is an increased risk of thrombosis. All pregnant women are therefore at risk of thrombosis, compared with non-pregnant women. This risk is manifest from early in the first trimester until 4−6 weeks post partum.

one year ago
Routine laboratory factors predict adverse pregnancy outcomes of patients with intrahepatic cholestasis of pregnancy, according to a prospective, case control study.